Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2025 ,inter alia, to consider and approve 1. To consider and approve the Unaudited Financial Results of the Company for the 1st quarter endedon 30th June, 2025.2. To change the Corporate Office of the Company.3. To appoint Mr. Ravi Thakor (DIN 11210729) as an Additional Non- Executive Non- IndependentDirector of the Company.4. To appoint Mr. Yogeshkumar Prajapati (DIN 11210767) as an Additional Non- ExecutiveIndependent Director of the Company.5. To appoint Mrs. Bhumika Pradhan (DIN 10167275) as an Additional Non- Executive IndependentDirector of the Company.6. To consider any other matter, with the permission of the Chair.
Welcure Drugs And Pharmaceuticals Ltd. Press Release Jul 31 2025
Filed with BSE · · 1 page · English
Release
Welcure Drugs and Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Welcure Drugs and Pharmaceuticals
- Welcure Drugs And Pharmaceuticals Ltd. Press Release Jul 21 2025
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Welcure Drugs And Pharmaceuticals Ltd. Press Release Jul 08 2025
- Completion Of Export-Sourcing Orders Aggregating Rs. 299.91 Crores
- Welcure Wins New? 856 Million Export-Sourcing Orders From Giant Exim & Ravina International - Reg-30 Disclosure
Later from Welcure Drugs and Pharmaceuticals
- Board Meeting Outcome for Outcome Of Board Meeting
- Standalone Unaudited Financial Results For The 1St Quarter Ended 30Th June 2025
- Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Announcement under Regulation 30 (LODR)-Change in Management
- Announcement under Regulation 30 (LODR)-Resignation of Director
Follow Welcure Drugs and Pharmaceuticals into a list and get an email when it puts out news.
Follow Welcure Drugs and Pharmaceuticals